We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · June 30, 2021

Factors Associated With Switching From Sulfonylureas to DPP-4 Inhibitors

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Factors Associated With Switching From Sulfonylureas to Dipeptidyl Peptidase 4 Inhibitors Among Patients With Type 2 Diabetes in the United States
Diabetes Obes Metab 2021 Jun 15;[EPub Ahead of Print], X Tan, L Yang, K Khunti, R Zhang, Y Zhang, S Rajpathak, M Yu

Further Reading